Default company panoramic image

tonus therapeutics

We are developing a peptide therapeutic to treat Muscular Dystrophy. The peptide may be useful for treating many other diseases.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Williamsville, NY, USA
  • Currency USD
  • Employees 4
  • Website

Company Summary

Duchenne dystrophy affecting 1 in 3500 boys and there is no cure or therapy but our company has a patented orphan drug. Gsmtx4 is a peptide inhibits mechanosensitive ion channels activated only by pathologic stress. It is a unique peptide, non toxic to animals, and is currently undergoing preclinical trials. It has demonstrated applications beyond dystrophy including atrial fibrillation, incontinence and sickle cell anemia.


  • Default avatar
    Frederick Sachs

  • Default avatar
    Thomas Suchyna
    VP of Research

  • Default avatar
    Jeff Harvey

  • Default avatar
    Phillip Gottlieb
    Chief Scientist